

CURRICULUM VITAE

Date of Revision: March 15, 2024
Name: David N. Assis, MD
Associate Professor, Department of Internal Medicine, Section of
Digestive Diseases, Clinician Educator Track
School: Yale School of Medicine

Education:

BS, Messiah College 2001
MD, Jefferson Medical College 2005

Career/Academic Appointments:

2005 - 2006 Internship, Medicine, Thomas Jefferson University, Hospital, Philadelphia, PA
2006 - 2008 Residency, Medicine, Thomas Jefferson University Hospital, Philadelphia, PA
2008 - 2009 Chief Residency, Medicine, Thomas Jefferson University Hospital, Philadelphia, PA
2009 - 2012 T32 Fellowship, Gastroenterology, Yale School of Medicine, New Haven, CT
2012 - 2013 Transplant Hepatology Fellowship, Yale School of Medicine, New Haven, CT
2013 - 2014 Instructor, Digestive Diseases, Yale School of Medicine, New Haven, CT
2014 - 2020 Assistant Professor, Digestive Diseases, Yale School of Medicine, New Haven, CT
2020 – present Associate Professor, Digestive Diseases, Yale School of Medicine, New Haven, CT
2021 – present GI/Liver Fellowship Program Director, Yale School of Medicine, New Haven, CT

Board Certification:

AB of Internal Medicine, Internal Medicine, 08-2008, 12-2018, 11-2020
AB of Internal Medicine, Gastroenterology, 10-2012
AB of Internal Medicine, Transplant Hepatology, 10-2014

Professional Honors & Recognition:

International/National/Regional

2023 Connecticut Magazine, Connecticut's Best Doctors 2023
2022 Connecticut Magazine, Connecticut's Best Doctors 2022
2020 Connecticut Magazine, Connecticut's Best Doctors 2020
2019 Connecticut Magazine, Connecticut's Best Doctors 2019
2016 American Liver Foundation - Connecticut Chapter, Rising Professional Award
2003 Association of Pathology Chairs, Association of Pathology Chairs National Pathology
Honor Society
1999 Sigma Zeta, Sigma Zeta National Science and Mathematics Honor Society

Yale School of Medicine

- 2014 Yale Section of Digestive Diseases, 2014 Kushlan Junior Faculty Award
- 2012 Yale Section of Digestive Diseases, Samuel Kushlan Fellowship Award for Excellence in Research

Other

- 2006 Thomas Jefferson University Hospital, Intern of the Year Award
- 2005 Jefferson Medical College, Alexander and Lottie Katzman Award in Gastroenterology
- 2005 Jefferson Medical College, Frans J. Vossenber Memorial Prize in Internal Medicine
- 2005 Jefferson Medical College, J. Woodrow Savacool Prize in Medical Ethics
- 2005 Jefferson Medical College, William F. Kellow Prize for Attributes of an Ideal Physician
- 2004 Jefferson Medical College, Alpha Omega Alpha (AOA) Medical Society
- 2003 Jefferson Medical College, Hobart Armory Hare Honor Medical Society
- 2001 Messiah College, Graduation Summa Cum Laude
- 2000 Messiah College, Ray H. Crist Research Scholarship Award

Invited Speaking Engagements, Presentations, Symposia & Workshops Not Affiliated With Yale:

International/National

- 2023: Food and Drug Administration (FDA) – “Insights into Primary Sclerosing Cholangitis: Clinical Trial Endpoints”. Delivered virtually to FDA Liver Division by invitation on December 1, 2023.
- 2023: AASLD Liver Meeting -- Meet the Expert Session: “Organoids to Model and Develop New Treatments for Liver Disease”. Co-delivered with Dr. Burcin Ekser in Boston, MA on November 11, 2023.
- 2023: AASLD Liver Meeting -- Meet the Expert Session: “How to Manage Insufficient Response to UDCA in Primary Biliary Cholangitis”. Co-delivered with Dr. Marlyn Mayo in Boston, MA on November 11, 2023.
- 2023: PSC Partners Seeking a Cure Annual Meeting: “PSC 101.” Invited presentation delivered in Henderson, Nevada, September 8, 2023.
- 2023: AASLD Emerging Topic Conference: Multi-Omics Approaches for Cholestatic Liver Diseases: From Diagnosis to Disease Mechanisms and Precision Medicine: “Personalized Medicine from Clinical Biospecimens.” Delivered recording virtually on June 1, 2023.
- 2023: International PSC Study Group (IPSCSG) Young Investigator Symposium: “Biliary-Immune Cross Talk.” Delivered in Hamburg, Germany on May 26, 2023.
- 2023: EASL Monothematic Conference on Biliary Fibrosis: “The Past and the Present of PBC and PSC Treatment: Where are we going?” Delivered in Florence, Italy on May 12, 2023.
- 2023: Digestive Disease Week (DDW): “Treatment of the Patient with early PSC: UDCA, Vancomycin, or Neither?” Delivered in Chicago, Illinois on May 8, 2023.
- 2023: UC Davis Annual Liver Research Day: “Second Line Treatment of PBC: Obeticholic Acid or Fenofibrate?” Delivered at Davis, California on April 21, 2023.

- 2023: University of Birmingham (UK) Medical Center: “Insights on Primary Sclerosing Cholangitis (PSC) through Bile-Derived Organoids” invited presentation in person to faculty and trainees at Birmingham Medical Center (UK) as part of mini-sabbatical at that center – March 10, 2023.
- 2023: University of Birmingham (UK) Medical Center: “Updates in Autoimmune Hepatitis” invited presentation in person to faculty and trainees at Birmingham Medical Center (UK) as part of mini-sabbatical at that center – March 9, 2023.
- 2022: Albert Einstein Montefiore Medical Center GI Grand Rounds: “Updates on the Management of PBC and PSC” presented virtually on December 1, 2022.
- 2022: North American Cystic Fibrosis Conference (NACFC): “New Guidelines on Cystic Fibrosis Liver Disease: Screening and Diagnosis” invited in person presentation at the national conference – November 3, 2022.
- 2022: VA-SCAN Liver Education Series: “Updates in Autoimmune and Cholestatic Liver Diseases” presented virtually to Veterans Affairs physician audience – August 23, 2022.
- 2022: Invited Speaker at Indiana University Center for Liver Research - “Bile-Derived Organoids: A Novel Approach to the Study of Primary Sclerosing Cholangitis” – presented on August 22, 2022, Indianapolis, IN, USA. Hosted by Dr Gianfranco Alpini and Dr. Heather Francis.
- 2022: 4th International Autoimmune Hepatitis Group Workshop – “Regulatory T-cells in Autoimmune Hepatitis” – presented on June 3, 2022, Maastricht, Netherlands.
- 2022: 4th International Autoimmune Hepatitis Group Workshop – New Immunomodulatory Treatments in AIH – breakout session co-presented and co-moderated on June 3, 2022, Maastricht, Netherlands.
- 2022: Digestive Disease Week (DDW) – “Novel Diagnostic and Prognostic Biomarkers in Autoimmune Hepatitis” – presented on May 22, 2022, San Diego, California.
- 2022: Digestive Disease Week (DDW) – “AASLD Practice Guidance: Primary Sclerosing Cholangitis and Cholangiocarcinoma” – presented on May 23, 2022, San Diego, California.
- 2022: GI Grand Rounds at Tufts Medical Center – Update in Primary Sclerosing Cholangitis – presented virtually on April 14, 2022.
- 2021: Cystic Fibrosis Foundation Annual North American Cystic Fibrosis Conference (NACFC) --- Clinical Symposium S03: Updates in CF Liver Disease. Gave a presentation entitled “The Role of Imaging for CF-Associated Liver Abnormalities” and participated as a panelist, November 3, 2021 (virtual).
- 2021: PSC Partners Seeking a Cure – ROADMAP Series Webinar 301 – The PSC Research Landscape: Now and Into the Future Charting a Path Forward – Was a panelist of national experts on PSC discussing research priorities for the field. Also co-moderated a breakout session for the Webinar, October 26, 2021 (virtual).
- 2021: 26th Congress of Brazilian Hepatology (Congresso Brasileiro de Hepatologia) --- “Primary Sclerosing Cholangitis” --- lecture delivered in Portuguese do the Brazilian Society of Hepatology (Sociedade Brasileira de Hepatologia) at their annual meeting, October 8, 2021 (virtual).
- 2021: PSC Partners Seeking a Cure – ROADMAP Series Webinar 201 – The PSC Research Landscape: Now and Into the Future Identifying Research Questions – Presented a segment on “The Role of Immune Cells in PSC” to a national audience of patients, advocates, and researchers. Also co-moderated a breakout session for the Webinar, September 29, 2021 (virtual).
- 2021: American Liver Foundation (National Patient Advocacy Organization) Ask the Experts Program -- - co-presented a session dedicated to patient education on Primary Biliary Cholangitis, September 14, 2021 (virtual).
- 2021: Virginia/DC/Maryland Cystic Fibrosis Network Journal Club Conference --- presented a journal club and teaching session on Cystic Fibrosis Liver Disease, September 9, 2021 (virtual).

- 2021: Autoimmune Hepatitis Association 2021 Virtual Conference --- Co-panelist with 2 other hepatologists at a national virtual live educational event for patients with autoimmune hepatitis, June 25, 2021 (virtual).
- 2021: Autoimmune Hepatitis: First-Line Therapy in 2021 --- Lecture Presented at the International Liver Congress (ILC) of the European Association for the Study of the Liver (EASL), Virtual Annual Meeting, June 24, 2021 (virtual).
- 2021: The Future of GI Health in Cystic Fibrosis --- Session Co-Presented during the Rutgers University CF Family Day Virtual Event, April 17, 2021 (virtual).
- 2020: Update on New Autoimmune Hepatitis Guidelines --- AASLD Liver Meeting Digital Experience. Presentation delivered at the national meeting on November 15, 2020 (virtual).
- 2019: International Autoimmune Hepatitis Group 3rd International Workshop --- Medical University of Vienna, Vienna, Vienna, Austria. "Workshop Session Co-Moderator", July 2019.
- 2019: PSC Partners Seeking a Cure Annual Meeting -- Mayo Clinic, Rochester, MN. "Management of PSC and Quality of Life"
- 2019: PSC Partners Seeking a Cure Annual Meeting -- Mayo Clinic, Rochester, MN. "PSC Partners Supported Research"
- 2019: Autoimmune Hepatitis Association Patient Support and Education Weekend -- University of Indiana, Indianapolis, IN. "How is My Immune System Connected to Autoimmune Hepatitis?"
- 2019: Autoimmune Hepatitis Association Patient Support and Education Weekend -- University of Indiana, Indianapolis, IN. "New Research in Autoimmune Hepatitis"
- 2019: Autoimmune Hepatitis Association Patient Support and Education Weekend -- University of Indiana, Indianapolis, IN. "What to Expect after your Diagnosis of Autoimmune Hepatitis"
- 2019: Annual Digestive Disease Week (DDW) Meeting -- Post-Graduate Course, San Diego, CA. "Management of Autoimmune Liver Disease: Curbside Consult (Co-Presenter, and co-developer of syllabus content for this part of the Post-Graduate Course)"
- 2019: Annual Digestive Disease Week (DDW) Meeting, San Diego, CA. "Co-Moderator of Oral Abstract Parallel Session: Human Cholestatic and Autoimmune Liver Diseases"
- 2018: Annual Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA. "Primary Sclerosing Cholangitis (PSC) in Children vs. Adults (Co-Presenter of Meet-the-Professor Luncheon Lecture, and Co-Developed educational handout material for the session)"
- 2018: Annual Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA. "Immunopathogenesis of Autoimmune Hepatitis"
- 2018: Annual North American Cystic Fibrosis Conference, Denver, CO. "Liver Disease in the Adult CF Patient: Unique Aspects and Lessons for Pathophysiology (Delivered Lecture and Wrote Syllabus Content for this Talk)"
- 2018: 9th International Workshop on Macrophage Migration Inhibitor Factor (MIF), Munich, BY, Germany. "The role of Macrophage Migration Inhibitory Factor (MIF) in Autoimmune Liver Disease"
- 2018: Cincinnati Children's Hospital Medical Center: Annual Conference of the Hospital's Center for Autoimmune Liver Disease, Cincinnati, OH. "Update on Clinical Studies in Adults with Autoimmune Hepatitis and Primary Sclerosing Cholangitis"
- 2018: Annual Digestive Disease Week (DDW) Meeting, Washington, DC. "Co-Moderator of Oral Abstract Parallel Session on Autoimmune and Cholestatic Liver Disease"

- 2018: Thomas Jefferson University Hospital and Sidney Kimmel College of Medicine, Philadelphia, PA. "GI Grand Rounds: Emerging Advances in Primary Sclerosing Cholangitis"
- 2018: 5th International PSC Study Group Workshop, Paris, Île-de-France, France. "Co-Moderator of Workshop Session"
- 2017: Annual North American Cystic Fibrosis Conference, Indianapolis, IN. "Cystic Fibrosis Liver Disease (GI Short Course lecture)"
- 2017: Annual North American Cystic Fibrosis Conference, Indianapolis, IN. "Biliary complications of Cystic Fibrosis (GI Roundtable Talk)"
- 2017: Annual Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), Washington, DC. "Co-Moderator of Oral Abstract Parallel Session: Clinical Cholestasis"
- 2017: Cincinnati Children's Hospital Medical Center: Annual Conference of the Hospital's Center for Autoimmune Liver Disease, Cincinnati, OH. "The Natural History of adult onset Autoimmune Hepatitis and Primary Sclerosing Cholangitis"
- 2017: 8th International Macrophage Migration Inhibitory Factor (MIF) Meeting, Powerscourt Estate, County Wicklow, Ireland. "The Role of MIF in Autoimmune Liver Disease"
- 2016: Annual Liver Meeting of the Association for the Study of Liver Diseases (AASLD), Boston, MA. "Management of Refractory Pruritus (Co-Presenter of Meet-the-Professor Luncheon)"
- 2016: Annual North American Cystic Fibrosis Conference Meeting, Orlando, FL. "Cystic Fibrosis and Liver Transplantation (GI Roundtable Talk)"
- 2016: Albert Einstein Medical Center, Philadelphia, PA. "GI & Hepatology Grand Rounds: Autoimmune Hepatitis"
- 2015: Annual Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA. "Recurrent PBC and PSC after liver transplant (Co-presented an Early Morning Workshop and Co-developed educational handout material for the session)"
- 2015: Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA. "Nutrition and Metabolic Complications of Cholestasis"
- 2015: Annual North American Cystic Fibrosis Conference, Phoenix, AZ. "GERD in CF (GI Roundtable Talk)"
- 2015: PSC Partners Seeking a Cure Annual Meeting -- hosted by Baylor University Medical Center, Fort Worth, TX. "Update on Treatments in PSC"
- 2015: PSC Partners Seeking a Cure Annual Meeting -- hosted by Baylor University College of Medicine, Fort Worth, TX. "The Drug Approval Process (Presentation and Workshop)"
- 2014: Annual Liver Meeting of the American Association for the Study of Liver Diseases, Boston, MA. "New Therapies for PSC (Presentation at the Special Interest Group Event for Cholestatic and Biliary Diseases)"
- 2011: Annual Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA. "Management of very early hepatocellular carcinoma (<2 cm): Treat. (Co-author, with Dr. Mario Strazzabosco, of written material for the Post-Graduate Course Syllabus at the AASLD Liver Meeting."

Regional

- 2018: The Transplantation Society Education Committee International Webinar Series -- delivered from New Haven to international audience, New Haven, CT. "AIH, PBC and PSC -- Medical Considerations (International Webinar Series)"

- 2018: American Liver Foundation CT Chapter Medical Advisory Committee Meeting, Derby, CT. "Best of the AASLD Liver Meeting (Co-presenter of the session)"
- 2016: PSC Partners Seeking a Cure National Annual Meeting -- hosted by Yale University, New Haven, CT. "PSC from A to Z"
- 2016: PSC Partners Seeking a Cure National Annual Meeting -- hosted by Yale University, New Haven, CT. "Should I participate in a Clinical Trial?"
- 2016: 4th International PSC Study Group Workshop -- hosted by Yale University, New Haven, CT. "Defining Value Based Outcomes for PSC"
- 2016: Webinar Series from the American Association for the Study of Liver Diseases (AASLD) -- delivered from New Haven to a national webinar audience, New Haven, CT. "WEBINAR: Fibrates in the Context of Cholestatic Diseases: Basic Aspects (Co-Presenter of Webinar)"
- 2016: American Liver Foundation National Patient Advocate Training Program at the American Liver Foundation national headquarters, New York, NY. "Primary Biliary Cholangitis"
- 2016: American Liver Foundation CT Chapter Medical Advisory Committee Meeting, Wallingford, CT. "Primary Biliary Cholangitis"

Peer-Reviewed Presentations & Symposia Given at Meetings Not Affiliated With Yale:

International/National

- 2023: Harrington C, Krishnan S, Roberts S, Carroll A, Cravedi P, Kelleher N, Boyer JL, Silveira MG, Forte E, Assis DN, Levitsky J. Biomarker Discovery in Patients with Autoimmune Hepatitis. Poster Presentation at AAASLD Liver Meeting in Boston, MA November 14, 2023. *Hepatology*. 78(S1):S1-S2154, (Abstract 4502-C).
- 2023: Krishnan S, Roberts S, Deng Y, Leng L, Silveira MG, Bulcala R, Boyer JL, Assis DN. Investigating MIF as a Biomarker of Disease Severity in Autoimmune Hepatitis. Poster Presentation at AAASLD Liver Meeting in Boston, MA November 14, 2023. *Hepatology*. 78(S1):S1-S2154, (Abstract 4509-C).
- 2023: Evon DM, Merkler K, Reeve B, Anderson C, Safer R, Hatchett J, Gomel R, Bowlus CL, Assis DN. Symptoms of Primary Sclerosing Cholangitis (PSC) in the Last Month: Preliminary Data from the PSC-Partners Patient Reported Outcome Measure Project. Poster Presentation at AAASLD Liver Meeting in Boston, MA November 14, 2023. *Hepatology*. 78(S1):S1-S2154, (Abstract 4577-C).
- 2022: Chaar A, Qasim O, Mbachi C, Assis DN. Extrahepatic autoimmune diseases in patients with autoimmune hepatitis and primary biliary cholangitis varies widely by race: A nationwide study. Poster presentation at DDW, May 23, 2022 in San Diego, California.
- 2020: Soroka CJ, Roberts S, Hohenester S, Boyer JL, Assis DN. "Co-culture of Bile-Derived Organoids from PSC patients with CD4+ T-cells replicates pathogenic, CCL20 dependent biliary-immune interactions". Oral Abstract presented at the Digital International Liver Congress of the European Associated for the Study of the Liver (EASL), August 28, 2020.
- 2018: Annual Liver Meeting of the Association for the Study of Liver Diseases (AASLD), San Francisco, CA. "Auclair AM, Assis DN, Boyer JL, Ghonem NS. Fenofibrate Improved Cholestasis and Reduced Bile Acid Toxicity In Vivo. Oral abstract at the AASLD Liver Meeting, November 12, 2018, Abstract #263, Oral Presentation"
- 2018: Annual Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA. "Soroka CJ, Assis DN, et al. Bile-Derived Organoids from PSC Patients Recapitulate the Inflammatory Immune Profile Seen in Cholangiopathies, Providing an In Vitro

- Model to Test Candidate Therapeutic Agents. Poster at the AASLD Liver Meeting, November 12, 2018. Abstract #1901. Poster Presentation"
- 2018: Annual Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA. "Davis A, Celli R, Assis DN, Jain D. Network Analysis Approach to Autoimmune Hepatitis: A Novel and Unbiased Method to Identify Meaningful Clinical-Pathological Associations. Poster at the AASLD Liver Meeting, November 12, 2018, Abstract #1969. Poster Presentation"
- 2018: Annual Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA. "Alrabadi A, ..., Sinha R, Assis DN, Boyer JL. Mindfulness-Based Stress Reduction Improves Stress, Disease Activity and Cytokine Levels in Patients with Autoimmune Hepatitis (AIH). November 12, 2018. Abstract #1966. Poster Presentation."
- 2017: Annual International Liver Congress of the European Association for the Study of the Liver (EASL), Amsterdam, NH, Netherlands. "Roberts SJ, Leng L, Soroka CJ, Boyer JL, Bucala R, Assis DN. Macrophage Migration Inhibitory Factor (MIF) modulates T-cell proliferation and hepatic inflammation in a model of autoimmune liver disease. April 21, 2017, ILC2017-RS-2307. Poster Presentation"
- 2017: Annual Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), Washington, DC. "Roberts SJ, Leng L, Harry KM, Boyer JL, Bucala R, Assis DN. A small molecule inhibitor of Macrophage Migration Inhibitory Factor (MIF) significantly reduces liver injury in an antigen- and liver-specific pre-clinical model of autoimmune hepatitis (AIH). Abstract #113. Oral Presentation"
- 2016: Annual North American Cystic Fibrosis Conference, Orlando, FL. "Southard R, Rioux L, Cullinan M, Merritt K, Horvath M, Iezzi S, Rightmer N, Robaczynski C, Assis D, Britto C, Talwalkar J, Koff J. Multidisciplinary approach to improve inpatient care. Pediatric Pulmonology 2016;51(S45):A416: Abstract 582. Poster Presentation"
- 2016: Annual Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, MA. "Njei B, McCarty TR, Assis DN. Primary Biliary Cholangitis-Associated Hospitalizations in the US: A Nationwide Analysis, 2004-2012. Hepatology 2016;64 (S1):S205A: Abstract 402. Poster Presentation"
- 2016: Annual Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, MA. "McCarty TR, Cho M, Mitchell KA, Boyer JL, Assis DN. The Clinical Significance of IgG4 Positive Autoimmune Hepatitis. Hepatology 2016;64(S1):S818A: Abstract 1652. Poster Presentation"
- 2015: Annual North American Cystic Fibrosis Conference, Phoenix, AZ. "Lampugnale B, Mitson-Salazar A, Minor J, Iezzi S, DeRose C, Talwalkar J, Assis D, Britto C, Joff J. A quality improvement project to improve influenza vaccination rates in an adult Cystic Fibrosis Program. Pediatric Pulmonology 2015;51(S42):A395: Abstract 537. Poster Presentation"
- 2015: Annual North American Cystic Fibrosis Conference, Phoenix, AZ. "Robaczynski C, Ardito M, Merritt K, Sullivan-Kelley J, Rightmer N, Horvath M, Scatena R, Assis D, Talkalkar J, Britto C, Koff J. A quality improvement project to improve nutrition at an Adult CF Clinic. Pediatric Pulmonology 2015;51(S42):A416: Abstract 546. Poster Presentation."
- 2015: AASLD/EASL, London, England, United Kingdom. "Assis DN, Bucala R, Boyer JL. Macrophage migration inhibitory factor (MIF) may mediate the effect of Psychological Stress in Autoimmune

- Hepatitis (AIH). EASL/AASLD Monothematic Conference on Autoimmune Hepatitis. September 4. Poster Presentation"
- 2015: Annual Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA. "Assis DN, Bucala R, Boyer JL. Macrophage migration inhibitory factor (MIF) may mediate the effect of Psychological Stress in Autoimmune Hepatitis (AIH). *Hepatology* 2015;62(S1):SA363: Abstract 298. Poster Presentation"
- 2014: Annual Liver Meeting of the Association for the Study of Liver Diseases (AASLD), Boston, MA. "Assis DN, ..., Nkinin SW, Setchell KDR, Ciarleglio M, Lindor KD, Boyer JL. Efficacy Trial of All-trans Retinoic Acid (ATRA) in combination with Ursodeoxycholic Acid (UDCA) in Primary Sclerosing Cholangitis (PSC). *Hepatology* 2014;60(S1):SA346: Abstract 293. Poster Presentation"
- 2013: Young Investigators Forum, Controversies in Transplantation Conference, Breckenridge, CO. "Assis DN, ..., Emre S, Schilsky M. Boceprevir (BOC) based Triple Therapy (TTx) for Hepatitis C Recurrence after Liver Transplantation. Young Investigators Forum, Controversies in Transplantation Conference, March 1, 2013. Oral Presentation"
- 2013: Wilson Disease Association, Baltimore, MD. "Assis DN, Zimbrea P, Schilsky ML. The spectrum of psychiatric symptoms in Wilson Disease. Wilson Disease Association meeting, April 8, 2013. Poster Presentation."
- 2011: Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA. "Assis DN, ... Bucala R, Boyer JL. Macrophage Migration Inhibitory Factor (MIF) and its Receptor CD74 may mediate effects of Psychological Stress in Autoimmune Hepatitis (AIH). Poster presented at the AASLD Liver Meeting, November 2011. *Hepatology*. 2011;54:S913A: #1164. Poster Presentation."
- 2011: Annual Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA. "Assis DN, et al. Differential profiles of Macrophage Migration Inhibitory Factor (MIF) and its receptor CD74 in Autoimmune Hepatitis (AIH) compared to Primary Biliary Cirrhosis (PBC). AASLD Liver Meeting, November 2011. *Hepatology*. 2011;54:S912A: Abstract 1161. Poster Presentation"
- 2008: Annual Liver Meeting of the American Association for the Study of Liver Diseases, San Francisco, CA. "Assis DN, Read PJ, DeJesus J, Serper M, Linek JA, Herrine SK, Mitchell DG, Parker L, Rossi S, Navarro VJ. Magnetic Resonance Imaging (MRI) as a surrogate screening tool for esophageal varices in cirrhosis. *Hepatology*. 2008;Oct;48(Suppl 1), #731. Poster Presentation"
- 2007: Annual Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, MA. "Velez M, Assis DN, Alvarez-Posadilla M, Herrine SK, Rossi S, Navarro VJ. What motivates primary care providers to test for HCV? *Hepatology*. 2007;Oct; 46(4, Suppl 1):900A, #1479. Poster Presentation"
- 2007: Annual Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, MA. "Velez M, Assis DN, Alvarez-Posadilla M, Herrine SK, Rossi S, Navarro VJ. Primary care provider adherence to HCV testing recommendations. *Hepatology*. 2007;Oct; 46(4, Suppl 1):893A, #1464. Poster Presentation"
- 2006: American College of Physicians (Southeastern Region) Associates' Annual Competition., Abington, PA. "Assis DN, Zamfirescu I, Filicko J. Acute Lymphoblastic Leukemia presenting with Spontaneous Splenic Rupture - A Case Report. Poster Presentation"

- 2006: American College of Gastroenterology Annual Meeting, Las Vegas, NV. "Brotz CS, Assis DN, Ahmed M, Choudhary C. Metastatic adenocarcinoma of the esophagus in a 27 year old - A case report. American J Gastroenterol. 2006;101(9);s294-5: Abstract 722. Poster Presentation."
- 2006: Annual Digestive Disease Week (DDW) Meeting, Los Angeles, CA. "Sanaka MR, Banwait KS, Assis DN, Salese L, Thaker KM, Serper M, Kowalski TE, Loren DE. Poor correlation between endoscopic and histologic findings in the gastric antral vascular ectasia syndrome. Gastrointestinal Endoscopy. 2006;63(5):AB166: Abstract M1303. PMID: 16708434. Poster Presentation."
- 2006: Annual Digestive Disease Week (DDW) Meeting, Los Angeles, CA. "Banwait K, Sanaka MR, Thaker KM, Kwok K, Moleski S, Assis DN, Kowalski TE, Loren DE. Success of argon plasma coagulation for management of gastric antral vascular ectasia. Gastroenterology. 2006; 130(4, Suppl 2);A465: Abstract T1060. PMID: 16642574. Poster Presentation."
- 2003: Jefferson Medical College -- Annual Student Research Symposium for Pathology Honors Program., Philadelphia, PA. "Hepatitis C Virus: Mechanisms of Pathogenesis.Oral Presentation"
- 2001: National Annual Meeting of the American Scientific Affiliation., Manhattan, KS. "Assis DN, Mylin LM. Selection of Cytotoxic T Lymphocyte Clone Y-1 Escape Variants from Murine Fibroblasts Transformed by Simian Virus 40 Large Tumor Antigen. Oral Presentation"

Professional Service:

Peer Review Groups/Grant Study Sections

- 2021 National Institutes of Health – R01 Study Section, Ad hoc reviewer
- 2021 Cystic Fibrosis Ireland, Ad hoc reviewer
- 2019 Canadian Institutes of Health Research, Ad hoc reviewer
- 2023 AASLD Foundation Grants Committee
- 2023 American Liver Foundation Grants Committee

Thesis Committee

- 2022 – present External Member of PhD Thesis Committee for PhD candidate Jake Herb – Mount Sinai School of Medicine

Journal Service

Editorial Board

- 2021 – present Editorial Board Member, Hepatology

Reviewer

- 2022 – present Reviewer, American Journal of Physiology-Gastrointestinal and Liver Physiology, Ad hoc reviewer
- 2022 – present Reviewer, The Journal of Pathology, Ad hoc reviewer
- 2022 – present Reviewer, Frontiers in Immunology, Ad hoc reviewer
- 2022 – present Reviewer, American Journal of Gastroenterology, Ad hoc reviewer
- 2022 – present Reviewer, BMJ Open Gastroenterology, Ad hoc reviewer
- 2021 - present Reviewer, FASEB Journal, Ad hoc reviewer
- 2021 - present Reviewer, American Journal of Transplantation, Ad hoc reviewer
- 2021 – present Reviewer, Gastroenterology, Ad hoc reviewer

2020 - present Reviewer, Journal of Hepatology, Ad hoc reviewer
 2020 - present Reviewer, New England Journal of Medicine, Ad hoc reviewer
 2020 - present Reviewer, JCI Insight, Ad hoc reviewer
 2019 - present Reviewer, Alimentary Pharmacology and Therapeutics, Ad hoc reviewer
 2018 - present Reviewer, Hepatology Communications, Ad hoc reviewer
 2017 - 2018 Reviewer, Digestive Diseases and Sciences, Ad hoc reviewer
 2017 - present Reviewer, Liver Transplantation, Ad hoc reviewer
 2016 - present Reviewer, Clinical Gastroenterology and Hepatology, Ad hoc reviewer
 2015 - present Reviewer, Liver International, Ad hoc reviewer
 2013 - 2014 Reviewer, Arthritis & Rheumatology, Ad hoc reviewer
 2013 - present Reviewer, Hepatology, Ad hoc reviewer
 2012 - 2013 Reviewer, Cytokine, Ad hoc reviewer

Professional Service for Professional Organizations

American Association for the Study of Liver Diseases (AASLD)

2023 -- **Member**, Grant Foundation Committee
 2023 -- **Member**, AASLD Special Interest Group (SIG) Advisory Task Force
 2023 -- **Member At-Large**, AASLD Special Interest Group (SIG) on Cholestatic and Autoimmune Liver Diseases
 2020 – 2022 **Co-Chair**, AASLD Writing Group Task Force -- Guidance on Primary Sclerosing Cholangitis (PSC)/Cholangiocarcinoma
 2020 – 2022 **Chair**, AASLD SIG on Cholestatic and Autoimmune Liver Diseases
 2018 - 2019 **Writing Group Member**, AASLD Writing Group Task Force -- Guidelines on Autoimmune Hepatitis
 2018 - 2019 **Vice Chair**, AASLD SIG on Cholestatic and Autoimmune Liver Diseases
 2018 - present **Abstract Reviewer**, for AASLD sponsored National Meetings: The Liver Meeting and DDW
 2016 - 2017 **Secretary**, AASLD SIG on Cholestatic and Biliary Disorders
 2012 - 2013 **Fellow Member**, AASLD Clinical Research Committee

Cystic Fibrosis Foundation

2022 -- **Member**, Cystic Fibrosis Foundation Guidelines Committee
 2020 -- **Sub-group leader**, Cystic Fibrosis Foundation (CFF) Writing Group Task Force for developing the new Cystic Fibrosis Liver Disease Guidelines for the CFF

Autoimmune Hepatitis Association

2020 - present **Member**, Medical Advisory Committee

American Liver Foundation -- Connecticut Chapter

2023 -- **Member**, Grants Committee

2014 - 2021 **Board Member**, American Liver Foundation -- Connecticut Chapter, Board Member of the CT Chapter of the American Liver Foundation, and director of the Education Committee.

Yale Human Translational Immunology Group

2014 – **Member**

Food & Drug Administration (FDA)

2016 – Member, Food & Drug Administration (FDA), Member, as a Special Government Employee, of the Gastrointestinal Drugs Advisory Committee (GIDAC) which reviews and makes recommendations on new drug applications for GI and Liver Disorders.

Participated in the following Committee meetings:

- **April 7, 2016** at the FDA headquarters: Obeticholic Acid for PBC.
- **March 8, 2018** at the FDA headquarters (participated remotely): Tofacitinib for Ulcerative Colitis.
- **May 3, 2018** at the FDA headquarters (combined GIDAC-PAC meeting): NDA for stannosporfin injection for neonates with severe hyperbilirubinemia.
- **July 15, 2020** at the FDA headquarters (participated remotely due to COVID) – Meeting of the Cardiovascular and Renal Drugs Advisory Committee: Terlipression for Hepatorenal Syndrome.
- **July 14, 2021** (participated remotely due to COVID) – Meeting of the Gastroenterology and Urology Devices Panel: TransMedics® Organ Care System (OCS™) for resuscitation, preservation, and assessment of liver allografts.
- **June 8, 2022** (participated remotely due to COVID) – Meeting of the Pharmacy Compounding Advisory Committee for evaluation of Ammonium Tetrathiomolybdate.
- **May 19, 2023** – (participated remotely) – Meeting of the GIDAC to evaluate vote on Obeticholic Acid for NASH.

International Primary Sclerosing Cholangitis Study Group (IPSCSG)

2023 Expert Faculty Member at the IPSCSG Young Investigator Meeting on Translational Research in PSC in Hamburg, Germany on May 25 and 26, 2023.

2022 -- **Member**, Steering Committee

2017 – 2021 Member of the Working Group on Definitions in Primary Sclerosing Cholangitis

2016 - 2019 Participant, International Primary Sclerosing Cholangitis Study Group, Co-leader of the Working Group on Clinical Trial Design.

International Autoimmune Hepatitis Group

2023 – present **Member**, Steering Committee

North American Consortium for Autoimmune Liver Disease (CALiD)

2017 - present Member, North American Consortium for Autoimmune Liver Disease (CALiD)

PSC Partners Seeking a Cure

- 2023 -- **Advisory Member**, PSC-Partners Patient Reported Outcome Measure Project
2018 -- **Scientific Advisor**, PSC Partners Seeking a Cure, Member of the Scientific Medical Advisory Committee for this Patient Advocacy Organization. In this capacity, I participate in meetings about the organization and peer-review grant proposals for funding.

Meeting Planning/Participation

- 2016 Committee Member, International PSC Study Group (IPSCSG), Co-organizer of the first scientific meeting of the IPSCSG in the US, June 26-27, 2016 in New Haven CT hosted at Yale School of Medicine.
2016 Committee Member, PSC Partners Seeking a Cure, Co-organizer of the national PSC Partners meeting for patients and advocates in New Haven, June 24-26, 2016 hosted by Yale School of Medicine.
2015 Co-planner of the AASLD Special Interest Group (SIG) on Cholestatic and Biliary Disorders Symposium: Management of Complications of Cholestasis, November 13, 2015 in San Francisco, CA.
2014 Presenter/Speaker, Yale School of Medicine, Patient-Centered Value Based Medicine Symposium at Yale, April 4, 2014.

Mentorship

- 2016-2018** **Leina Alrabadi, MD** – pediatric hepatology fellow at Yale. Provided mentorship in autoimmune liver disease, career development, and in studies of autoimmune hepatitis and biliary organoids.
2020 -- **Swathi Krishnan, MD** – internal medicine resident and now GI fellow. Provided mentorship in autoimmune liver disease, career development, and in studies of autoimmune hepatitis.

Public Service

- 2017 - 2018 Mentor, Design for American -- Yale University Chapter, Mentored three Yale undergraduate students in their Design For American (DFA) project in which they conceived of, and developed, a patient-oriented educational brochure about Autoimmune Hepatitis.
2015 - 2018 Committee Member, Trinity Church on the Green, Member of the Vestry.
2015 - 2017 Committee Member, Trinity Church on the Green, Member of the Stewardship Committee.
2020 – 2023 Committee Member, Trinity Church on the Green, Member of the Vestry.

Bibliography:

Peer-Reviewed Original Research

1. Mylin LM, Schell TD, Epler M, Kusuma C, **Assis D**, Matsko C, Smith A, Allebach A, Tevethia SS. Diversity of escape variant mutations in Simian virus 40 large tumor antigen (SV40 Tag) epitopes selected by cytotoxic T lymphocyte (CTL) clones. *Virology* 2007, 364:155-68.
2. Rossi S, **Assis DN**, Awsare M, Brunner M, Skole K, Rai J, Andrel J, Herrine SK, Reddy RK, Navarro VJ. Use of over-the-counter analgesics in patients with chronic liver disease: physicians' recommendations. *Drug Safety* 2008, 31:261-70.
3. Verma SK, Mitchell DG, Bergin D, Lakhman Y, Austin A, Verma M, **Assis D**, Herrine SK, Parker L. Dilated cisternae chyli: a sign of uncompensated cirrhosis at MR imaging. *Abdominal Imaging* 2009, 34:211-6.
4. Kowalski T, Nathwani RA, **Assis D**, Salese L, Banwait K, Loren D. Post-sphincterotomy transampullary balloon dilation is a safe and effective technique. *Digestive Diseases And Sciences* 2009, 54:670-4.
5. **Assis DN**, Schilsky ML. Testing and management of thrombocytopenia and coagulopathy in the pre- and postliver transplant patient. *Minerva Gastroenterologica E Dietologica* 2010, 56:331-43.
6. Cimsit B, **Assis D**, Caldwell C, Arvelakis A, Taddei T, Kulkarni S, Schilsky M, Emre S. Successful treatment of fibrosing cholestatic hepatitis after liver transplantation. *Transplantation Proceedings* 2011, 43:905-8.
7. **Assis DN**, Lim JK. New pharmacotherapy for hepatitis C. *Clinical Pharmacology And Therapeutics* 2012, 92:294-305.
8. **Assis DN**, Leng L, Du X, Zhang CK, Grieb G, Merk M, Garcia AB, McCrann C, Chapiro J, Meinhardt A, Mizue Y, Nikolic-Paterson DJ, Bernhagen J, Kaplan MM, Zhao H, Boyer JL, Bucala R. The role of macrophage migration inhibitory factor in autoimmune liver disease. *Hepatology (Baltimore, Md.)* 2014, 59:580-91.
9. Tandon P, Ripoll C, **Assis D**, Wongcharatrawee S, Groszmann RJ, Garcia-Tsao G. The interpretation of hepatic venous pressure gradient tracings - excellent interobserver agreement unrelated to experience. *Liver International: Official Journal Of The International Association For The Study Of The Liver* 2016, 36:1160-6.
10. Kim BS, Stoppe C, Grieb G, Leng L, Sauler M, **Assis D**, Simons D, Boecker AH, Schulte W, Piecychna M, Hager S, Bernhagen J, Pallua N, Bucala R. The clinical significance of the MIF homolog d-dopachrome tautomerase (MIF-2) and its circulating receptor (sCD74) in burn. *Burns: Journal Of The International Society For Burn Injuries* 2016, 42:1265-76.
11. **Assis DN**, Takahashi H, Leng L, Zeniya M, Boyer JL, Bucala R. A Macrophage Migration Inhibitory Factor Polymorphism Is Associated with Autoimmune Hepatitis Severity in US and Japanese Patients. *Digestive Diseases And Sciences* 2016, 61:3506-3512.
12. **Assis DN**, Abdelghany O, Cai SY, Gossard AA, Eaton JE, Keach JC, Deng Y, Setchell KD, Ciarleglio M, Lindor KD, Boyer JL. Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study. *Journal Of Clinical Gastroenterology* 2017, 51:e11-e16.
13. Goldberg D, Levy C, Yimam K, Gordon S, Forman L, Verna E, Yu L, Rahimi R, Schwarz K, Eksteen B, Pratt D, Boyer T, **Assis D**, Bowlus C. Primary Sclerosing Cholangitis Is Not Rare Among Blacks in a Multicenter North American Consortium. *Clin Gastroenterol Hepatol* 2018, 16:591-593.

14. Gurung A, **Assis DN**, McCarty T, Mitchell KA, Boyer JL, Jain D. Histologic features of autoimmune hepatitis: a critical appraisal. *Human Pathology* 2018, 82:51-60.
15. Soroka CJ, **Assis DN**, Alrabadi LS, Roberts S, Cusack L, Jaffe AB, Boyer JL. Bile-Derived Organoids From Patients With Primary Sclerosing Cholangitis Recapitulate Their Inflammatory Immune Profile. *Hepatology (Baltimore, Md.)* 2019, 70:871-882.
16. Hakim A, Zhang X, DeLisle A, Oral EA, Dykas D, Drzewiecki K, **Assis DN**, Silveira M, Batisti J, Jain D, Bale A, Mistry PK, Vilarinho S. Clinical utility of genomic analysis in adults with idiopathic liver disease. *Journal Of Hepatology* 2019, 70:1214-1221.
17. Lynch KD, Chapman RW, Keshav S, Montano-Loza AJ, Mason AL, Kremer AE, Vetter M, de Krijger M, Ponsioen CY, Trivedi P, Hirschfield G, Schramm C, Liu CH, Bowlus CL, Estes DJ, Pratt D, Hedin C, Bergquist A, de Vries AC, Janneke van der Woude C, Yu L, **Assis DN**, Boyer J, Ytting H, Hallibasic E, Trauner M, Marschall HU, Daretti LM, Marzioni M, Yimam KK, Perin N, Floreani A, Beretta-Piccoli BT, Rogers JK, Levy C. Effects of Vedolizumab in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. *Clin Gastroenterol Hepatol* 2020, 18:179-187.
18. Kim HP, Lieber SR, Rogers ME, Moon AM, Loiselle M, Walker J, **Assis DN**, Safer R, Gomel R, Evon DM. A Systematic Review of Patient-Reported Outcomes in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. *Hepatology Commun.* 2020, 4:1502-1515.
19. Ghonem NS, Auclair AM, Hemme CL, Galluci GM, de la Rosa Rodriguez R, Boyer JL, **Assis DN**. Fenofibrate improves liver function and reduces the toxicity of the bile acid pool in patients with PBC and PSC who are partial responders to Ursodiol. *Clin Pharmacol Ther* 2020, 108:1213-1223.
20. Efe C, Dhanasekaran R, Lammert C, Ebi B, Higuera-de la Tijera F, Aloman C, Riza Calışkan A, Peralta M, Gerussi A, Massoumi H, Catana AM, Torgutalp M, Purnak T, Rigamonti C, Gomez Aldana AJ, Khakoo N, Kacmaz H, Nazal L, Frager S, Demir N, Irak K, Ellik ZM, Balaban Y, Atay K, Eren F, Cristoferi L, Batıbay E, Urzua Á, Snijders R, Kiyıcı M, Akyıldız M, Ekin N, Carr RM, Harputoğlu M, Hatemi I, Mendizabal M, Silva M, Idilman R, Silveira M, Drenth JPH, **Assis DN**, Björnsson E, Boyer JL, Invernizzi P, Levy C, Schiano TD, Ridruejo E, Wahlin S. Outcome of COVID-19 in Patients with Autoimmune Hepatitis: an International Multi-Centre Study. *Hepatology.* 2021, 73:2099-2109.
21. Gallucci GM, Trottier J, Hemme C, **Assis DN**, Boyer JL, Barbier O, Ghonem NS. Adjunct fenofibrate up-regulates bile acid glucuronidation and improves treatment response for patients with cholestasis. *Hepatology Commun.* 2021; 5:2035-51.
22. Ponsioen CY, **Assis DN**, Boberg KM, Bowlus CL, Deneau M, Thorburn D, Aabakken L, Färkkilä M, Petersen B, Rupp C, Hübscher SG; IPSCSG. Defining Primary Sclerosing Cholangitis: Results from an International PSC Study Group consensus process. *Gastroenterology.* 2021;161:1764-75.
23. Efe C, Lammert C, Taşçılar K, Dhanasekaran R, Ebik B, Higuera-de la Tijera F, Calışkan AR, Peralta M, Gerussi A, Massoumi H, Catana AM, Purnak T, Rigamonti C, Aldana AJG, Khakoo N, Nazal L, Frager S, Demir N, Irak K, Melekoğlu-Ellik Z, Kacmaz H, Balaban Y, Atay K, Eren F, Alvares-da-Silva MR, Cristoferi L, Urzua Á, Eşkazan T, Magro B, Snijders R, Barutçu S, Lytvayak E, Zazueta GM, Demirezer-Bolat A, Aydın M, Heurgue-Berlot A, De Martin E, Ekin N, Yıldırım S, Yavuz A, Bıyık M, Narro GC, Kiyıcı M, Akyıldız M, Kahramanoğlu-Aksoy E, Vincent M, Carr RM, Günşar F, Reyes EC, Harputluoğlu M, Aloman C, Gatselis NK, Üstündağ Y, Brahm J, Vargas NCE, Güzelbulut F, Garcia SR, Aguirre J, Anders M, Ratusnu N, Hatemi I, Mendizabal M, Floreani A, Fagiuoli S, Silva M, Idilman R, Satapathy SK, Silveira M, Drenth JPH, Dalekos GN, **Assis DN**, Björnsson E, Boyer JL, Yoshida EM, Invernizzi P, Levy C, Montano-Loza AJ, Schiano TD, Ridruejo E, Wahlin S.. Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis. *Liver Int.* 2022;42:607-14.

24. Alrabadi LS, Dutton A, Rabiee A, Roberts SJ, Deng Y, Cusack L, Silveira MG, Ciarleglio M, Bucala R, Sinha R, Boyer JL*, **Assis DN*** (co-senior authors). Mindfulness-based stress reduction may decrease stress, disease activity and inflammatory cytokine levels in patients with autoimmune hepatitis. *JHEP Rep.* 2022;4:100450.
25. Gallucci GM, Alsuwayt B, **Assis DN**, Boyer JL, Ghonem NS. Fenofibrate downregulates NF-kB signaling to inhibit proinflammatory cytokine secretion in human THP-1 macrophages and during adult cholestasis. *Inflammation* 2022 Dec;45:2570-2581.
26. Li X, Li Y, Xiao J, Wang H, Guo Y, Mao X, Shi P, Hou Y, Zhang X, Zhao N, Zheng M, He Y, Ding J, Tan Y, Liao M, Li L, Peng Y, Li X, Pan Q, Xie Q, Li Q, Li J, Li Y, Chen Z, Huang Y, **Assis DN**, Cai SY, Boyer JL, Huang X, Tang CE, Liu X, Peng S, Chai J. Unique DUOX2+ACE2+ small cholangiocytes are pathogenic targets for primary biliary cholangitis. *Nat Commun* 2023;14:29.
27. Sayed A, **Assis DN**, Silveira MG, Deng Y, Ciarleglio M, Gaidos JKJ, Proctor DD, Al-Bawardy B. Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease. *Eur J Gastroenterol Hepatol.* 2023;35:270-274.
28. Zheng M, Hakim A, Konkwo C, Deaton AM, Ward LD, Alnylam Human Genetics, Silveira MG, **Assis DN**, Liapakis A, Jaffe A, Jiang ZG, Curry MP, Lai M, Cho MH, Dykas D, Bale A, Mistry PK, Vilarinho S. Advancing Diagnosis and Management of Liver Disease in Adults Through Exome Sequencing. *eBiomedicine.* 2023;95:104747.

Chapters, Books, and Reviews

29. **Assis DN**, Navarro VJ. Human drug hepatotoxicity: a contemporary clinical perspective. *Expert Opinion On Drug Metabolism & Toxicology* 2009, 5:463-73.
30. Ghonem NS, **Assis DN**, Boyer JL. Fibrates and cholestasis. *Hepatology (Baltimore, Md.)* 2015, 62:635-43.
31. **Assis DN**, Freedman SD. Gastrointestinal Disorders in Cystic Fibrosis. *Clinics In Chest Medicine* 2016, 37:109-18.
32. Bowlus CL, **Assis DN**, Goldberg DS. Zakim and Boyer's Hepatology: A Textbook of Liver Disease. Elsevier (7th Edition).
33. **Assis DN**. Chronic Complications of Cholestasis: Evaluation and Management. *Clinics In Liver Disease* 2018, 22:533-544.
34. Soroka CJ, **Assis DN**, Boyer JL. Patient-Derived Organoids from Human Bile: An In Vitro Method to Study Cholangiopathies. *Methods In Molecular Biology (Clifton, N.J.)* 2019, 1981:363-372.
35. Taylor SA, **Assis DN**, Mack CL. The Contribution of B Cells in Autoimmune Liver Diseases. *Semin Liv Dis.* 2019, 39:422-431.
36. **Assis DN**. The Immunopathogenesis of Autoimmune Hepatitis. *Clin Liver Dis (Hoboken).* 2020, 15:129-132.
37. Soroka CJ, Boyer JL, **Assis DN**. Review: Role of Biliary Organoids in Cholestasis Research and Regenerative Medicine. *Semin Liver Dis.* 2021; 41:206-212.
38. Harrington C, Krishnan S, Mack CL, Crevedi P, **Assis DN***, Levistky J*. (*co-senior authors). Non-invasive biomarkers for the diagnosis and management of autoimmune hepatitis. *Hepatology* 2022 Dec;76:1862-1879.

39. Velez C, Freedman SD, **Assis DN**. Advancing the GI Frontier in Cystic Fibrosis. *Clin Chest Med* 2022;43:743-755.
40. **Assis DN**, Bowlus CL. Recent Advances in the management of primary sclerosing cholangitis. *Clin Gastroenterol Hepatol* 2023;21:2065-2075.

Invited Editorials and Commentaries

41. **Assis DN**, Levy C. Editorial: environmental risk factors for PSC with and without IBD--the story unfolds. *Alimentary Pharmacology & Therapeutics* 2015, 41:1214-6.
42. Shung DL, **Assis DN**. Machine Learning in a Complex Disease: PREsTo Improves the Prognostication of Primary Sclerosing Cholangitis. *Hepatology* 2020, 71:8-10.
43. **Assis DN**, Levy C. Oral Vancomycin or Ursodeoxycholic Acid for Pediatric Primary Sclerosing Cholangitis? The Uncontroversial Need for Randomized Controlled Trials. *Hepatology*. 2021, 73:887-889.
44. **Assis DN**. Advancing Second-Line Treatment for Primary Biliary Cholangitis. *N Engl J Med*. 2024,390:853-4.

Practice Guidelines, Standards and Consensus Statements

45. **Assis DN**, Debray D. Gallbladder and bile duct disease in Cystic Fibrosis. *Journal Of Cystic Fibrosis: Official Journal Of The European Cystic Fibrosis Society* 2017, 16 Suppl 2:S62-S69.
46. Mack CL, Adams D, **Assis DN**, Kerkar N, Manns MP, Mayo MJ, Vierling JM, Alsawas M, Murad MH, Czaja AJ. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. *Hepatology* 2020, 72:671-722
47. Vierling JM, Kerkar N, Czaja AJ, Mack CL, Adams D, **Assis DN**, Manns MP, Mayo MJ, Nayfeh T, Mounaem MM, Alzuabi MA, Ding J, Haffar Sm, Murad MH, Alsawas M. Immunosuppressive Treatment Regimens in Autoimmune Hepatitis: Systematic Reviews and Meta-Analyses Supporting AASLD Guidelines. *Hepatology* 2020, 72:753-769.
48. Bowlus CL, Arrive L, Bergquist A, Deneau M, Forman L, Ilyas SI, Lundsford KE, Martinez M, Sapisochin G, Shroff R, Tabibian JH, **Assis DN**. AASLD Practice Guidance: Primary Sclerosing Cholangitis and Cholangiocarcinoma. *Hepatology* 2023;77:659-702.
49. Snijders R JALM, **Assis DN**, Oo YH, Sebode M, Taubert R, Willemse J, Tomsin B, Lohse AW, Drenth J PH, Gevers T JG. Research gaps and opportunities in autoimmune hepatitis – results of the International Autoimmune Hepatitis Group Research Workshop 2022. *Liv Int* 2023;43:1375-1384.

Case Reports, Technical Notes, Letters

50. **Assis DN**, Pollak J, Schilsky ML, Emre S. Successful treatment of a bleeding umbilical varix by percutaneous umbilical vein embolization with sclerotherapy. *Journal Of Clinical Gastroenterology* 2012, 46:115-8.
51. Plotkin E, **Assis DN**, Boyer JL. Now you see it, now you don't. *Hepatology*. 2013;58:446-447 (Case Report)

52. Guercio BJ, Iyer G, Kidwai WZ, Lacouture ME, Ghafoor S, Rossi AM, **Assis DN**, Chen YB, Busam KJ, Janjigian YY, Jhaveri K, Feldman DR, Capozzi A, Figueroa V, Bajorin DF, Rosenberg JE, Hollmann TJ, Funt SA. Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report. *Case Rep Oncol*. 2021, 14:430-438.

Scholarship in Press

53. Sellers ZM, **Assis DN**, Paranjape SM, Sathe M, Bodewes F, Bowen M, et al. Guidelines for screening, monitoring and treatment of Hepatobiliary Disease in Cystic Fibrosis from the Cystic Fibrosis Foundation Liver Disease Guidelines Committee. *Hepatology*. 2023 (*in press*).
54. Yazdanfar M, Zepeda J, Dean R, Wu J, Levy C, Goldberg D, Lammert C, Prenner S, Reddy KR, Pratt D, Forman L, **Assis DN**, Lytvyak E, Montano-Loza AJ, Gordon SC, Carey EJ, Ahn J, Schlansky B, Korzenik J, Karagozian R, Hameed B, Chandra S, Yu L, Bowlus CL. African American Race Does Not Confer an Increased Risk of Clinical Events in Patients with Primary Sclerosing Cholangitis. *Hepatol Comm*. 2023 (*in press*).
55. Kochhar S, **Assis DN**, Mack C, Izurieta HS, Muratori L, Munoz A, Nordenberg D, Gidudu JF, Blau EF, Vierling JM. Autoimmune hepatitis: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunization safety data. *Vaccine* 2023 (*in press*).
56. Kasper VL, **Assis DN**. Pathophysiology of Cystic Fibrosis Liver Disease. *Ped Pulm* (*in press*).